LifeScience Investors Group AG has a clear focus on the pharmaceutical, medical technology and services sectors (e.g. hospitals), but also
acquires companies in special situations (e.g. strategic non-core carve-outs, companies facing restructuring).
INDUSTRIES
The focus of LifeScience Investors Group AG investments is on the management and operation of worldwide non-core manufacturing sites of the pharmaceutical industries. We invest into API sites like antibiotic-contaminated infrastructures.
NUMBER IN SHARES
LifeScience Investors Group AG usually acquires all the shares or at least a qualified majority of the shares in the target companies or activities.
TURNOVER VOLUME
LifeScience Investors Group AG has no geographic focus of its activities but invests in worldwide pharmaceutical manufacturing sites. Our strategic focus lies on the onshoring of global manufacturing activities into the European and U.S. regulatory environment as part of our “buy-and-build” strategy.
INSUFFICIENT PROFITABILITY AND DECLINING REVENUES
Annual turnovers of target companies should range between € 10 and 300 million. However, smaller companies or parts of companies are also of interest to the LifeScience Investors Group AG if they add value to our existing investments.
INSUFFICIENT PROFITABILITY AND DECLINING REVENUES
LifeScience Investors Group AG also acquires companies or parts of companies that are in a restructuring situation and are facing insufficient financial or operational profitability or sales, or are struggling with environmental, legal or organizational problems.
STRATEGIC OR OPERATIONAL PROBLEM SITUATIONS
LifeScience Investors Group AG offers a future-proof solution for companies or activities that have not been able to develop adequately due to a strategic non-core activity or form an operational problem for the current shareholders.
